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Objectives: The protozoan parasite Giardia lamblia causes giardiasis, a persistent diarrhoea. Nitro drugs such as
the nitroimidazole metronidazole and the nitrothiazolide nitazoxanide are used for the treatment of giardiasis.
Nitroreductases may play a role in activating these drugs. G. lamblia contains two nitroreductases, GlNR1 and
GlNR2. The aim of this work was to elucidate the role of GlNR2.
Methods: Expression of GlNR2 was analysed by reverse transcription PCR. Recombinant GlNR2 was overex-
pressed in G. lamblia and drug susceptibility was analysed. Recombinant GlNR2 was subjected to functional
assays. Escherichia coli expressing full-length or truncated GlNR1 and GlNR2 were grown in the presence of
nitro compounds. Using E. coli reporter strains for nitric oxide and DNA damage responses, we analysed
whether GlNR1 and GlNR2 elicited the respective responses in the presence, or absence, of the drugs.
Results: G. lamblia trophozoites overexpressing GlNR2 were less susceptible to both nitro drugs as compared
with control trophozoites. GlNR2 was a functional nitroreductase when expressed in E. coli. E. coli expressing
GlNR1 was more susceptible to metronidazole under aerobic and semi-aerobic and to nitazoxanide under
semi-aerobic growth conditions. E. coli expressing GlNR2 was not susceptible to either drug. In reporter
strains, GlNR1, but not GlNR2, elicited nitric oxide and DNA repair responses, even in the absence of nitro drugs.
Conclusions: These findings suggest that GlNR2 is an active nitroreductase with a mode of action different from
that of GlNR1. Thus, susceptibility to nitro drugs may depend not only on activation, but also on inactivation of
the drugs by specific nitroreductases.
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Introduction
Giardia lamblia (syn. Giardia duodenalis; Giardia intestinalis), a fla-
gellated protozoan, is the most common causative agent of per-
sistent diarrhoea worldwide.1,2 For antigiardial chemotherapy,
some effective drugs are available, namely the nitroheterocyclic
drugs tinidazole, metronidazole, furazolidone, the acridine
derivative quinacrine, the aminoglycoside paromomycin, and
the benzimidazole albendazole.3,4 In 2000, the nitrothiazolide
nitazoxanide was introduced as an alternative option.5
According to a widely accepted hypothesis, metronidazole
and other related nitro drugs are reduced to a nitro radical by
electrons coming from the enzyme pyruvate:flavodoxin/ferre-
doxin oxidoreductase (PFOR), a protein lacking in higher eukary-
otic cells.6,7 According to this model, PFOR transfers electrons
from pyruvate to ferredoxin. The resulting reduced ferredoxin is
then reoxidized by ferredoxin:NAD oxidoreductase transferring
its electrons to NAD(P). The resulting NAD(P)H may then transfer
its electrons to O2, a reaction catalysed by NAD(P)H oxidase.
7 In
this model, nitro drugs may capture electrons directly from the
reduced ferredoxin or from the NAD(P)H oxidase, thus yielding
toxic radicals causing irreversible damage in the parasite.
Another line of evidence for PFOR as a main target for nitro
drugs in Giardia has been obtained in metronidazole-resistant
isolates, some of which exhibited lower PFOR expression levels.8
In the last decade, however, evidence has emerged that PFOR
may not be the only target of nitro drugs in semi-aerobic or an-
aerobic pathogens. Recent findings in Trichomonas vaginalis
suggest that metronidazole and other nitroimidazoles covalently
bind and thereby inactivate proteins related to the thioredoxin
reductase pathway. Resistant cells overcome this blocking by
reregulating other enzymes involved in oxidoreductive processes,
such as PFORs. In this model, down-regulation of PFOR would be
a consequence rather than a prerequisite of resistance forma-
tion.9 Moreover, recent studies on Giardia clones and strains re-
sistant against nitro drugs have revealed that resistance may
# The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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occur without down-regulation of PFOR.10,11 Therefore, it is likely
that there are alternative targets for nitro drugs, besides PFOR.
Although some nitro drugs seem to interact directly with PFOR,
it is unlikely that ferredoxin directly performs the reduction of
the nitro group. It is more probable that this reaction is catalysed
by nitroreductases.12 Nitroreductases are present in many
archaebacteria and eubacteria, where they allow the assimila-
tion of nitro compounds as carbon sources.13,14 Interestingly,
nitroreductases are also found in the genomes of microaerophilic
or anaerobic eukaryotic parasites, such as Entamoeba histolytica
and G. lamblia, which may have acquired them from prokaryotes
by lateral transfer.15
The genome of G. lamblia (clone WBC6) contains two genes
encoding nitroreductases, namely GlNR1 (accession no.
EDO80257) and GlNR2 (accession no. XM_764091.1). Whereas
GlNR1 has been characterized to some extent by our
group,11,16,17 detailed information concerning GlNR2 is lacking.
The polypeptide sequence of GlNR2 is highly similar to that of
GlNR1. Both proteins possess a ferredoxin domain with four
Fe-S clusters at their N terminus and a nitro-flavin mononucleo-
tide (FMN) reductase domain at their C terminus (Figure 1).
The potential for employing molecular genetic approaches in
Giardia, such as complementation of mutants, is very limited. In
addition, Giardia is restricted to anaerobic growth in a complex
medium, thus further narrowing its experimental potential.
Escherichia coli, however, grows under aerobic as well as under
semi-aerobic conditions in complex and defined media, and
offers a variety of molecular genetic tools, such as reporter
systems suitable for the heterologous expression and character-
ization of nitroreductases. NorR is a s54-dependent transcription
factor with a ferrous iron centre binding nitric oxide followed by
the activation of transcription of the norVW operon.18 The norV
promoter can be fused to lacZ, thus creating a suitable reporter
strain for nitric oxide stress.19 The reporter strain SOS-R1 is defi-
cient in major nitroreductases20,21 and carries a null mutation in
the multidrug efflux tolC gene, increasing susceptibility to various
drugs and antibiotics. Furthermore, this strain contains a fusion
between the SOS-inducible sfiA promoter and the lacZ reporter
gene and is thus suitable for a b-galactosidase-based
chromometric detection of antimicrobial compounds affecting
DNA replication.22 By introducing a heterologous nitroreductase
in this background, it is possible to investigate whether this
nitroreductase activates nitro compounds inducing DNA
damage.
Here, we present the characterization of GlNR2 by heterol-
ogous expression in G. lamblia and E. coli, and show that GlNR2
is a functional nitroreductase with properties different from
GlNR1.
Materials and methods
Tissue culture media, biochemicals and drugs
If not otherwise stated, all biochemical reagents were from Sigma
(St Louis, MO, USA). Nitazoxanide was synthesized at the Department
of Chemistry and Biochemistry, University of Berne (kindly provided by
Ch. Leumann). Nitroimidazole compound C17 was kindly provided by
J. A. Upcroft (Molecular Genetics Laboratory, Queensland Institute of
Medical Research, Brisbane, Australia). Nitazoxanide, metronidazole,
C17 and albendazole were kept as 100 mM stock solutions in DMSO at
2208C.
Axenic culture of Giardia trophozoites
Trophozoites from G. lamblia clone WBC6 as well as clones 713 and 10623
were grown under anaerobic conditions in 10 mL culture tubes (Nunc,
Roskilde, Denmark) containing modified TYI-S-33 medium. The
nitazoxanide-resistant clone C411 was maintained in the presence of
40 mM nitazoxanide, the metronidazole-resistant clones C5,11 713-M3
and 106-2ID1023 in the presence of 40 mM metronidazole, and the
C17-resistant clones 713-M3-C17 and 106-17A23 in the presence of
15 mM C17. Twenty-four hours prior to an experiment, the trophozoites
were transferred to drug-free, modified TYI-S-33 medium. Trophozoites
were detached by incubation on ice for 30 min. Suspended motile tropho-
zoites were counted (Neubauer chamber). Subcultures were initiated by
adding 2×10e4 trophozoites to a new culture tube. Trophozoites were
grown to near confluence and harvested by centrifugation (600 g,
15 min, 48C). Trophozoite pellets were washed three times with PBS, pH
7.2 and stored at 2808C.
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Figure 1. Alignment of GlNR2 (XM_764091.1) with the previously characterized nitroreductase GlNR1 (EDO80257). The alignment was produced with
ClustalW and edited with Boxshade. The conserved ferredoxin and nitro-FMN reductase domains are highlighted.
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Overexpression of recombinant GlNR2 in G. lamblia
Clones with high expression levels of the recombinant proteins were used
for the recloning of the GlNR1,17 GlNR2 (this study) and GusA (as a
control)17,24 open reading frames into the vector pPacV-Integ (kindly pro-
vided by A. Hehl, Institute of Parasitology, Zu¨rich, Switzerland). Applying
the XbaI and PacI sites of the vector for integration and taking into
account that the coding sequence of GlNR2 contained an XbaI site, a
forward primer was designed starting with an NheI site followed by the
constitutive glutamate dehydrogenase promoter. NheI creates an XbaI
isoschizomer, thus allowing cloning into an XbaI site. In the reverse
primer, a sequence encoding a human influenza haemagglutinin tag
was included upstream of the PacI site (Table S1, available as Supple-
mentary data at JAC Online). PCRs were performed using the pfu poly-
merase (Promega, Madison, WI, USA) and fragments were cloned into
the Zero Blunt TOPO vector (Invitrogen, Carlsbad, CA, USA), according
to the manufacturer’s instructions. Inserts were excised with NheI and
PacI and ligated into pPacV, thus yielding pPacV-GlNR2. Transfection
and selection of transgenic trophozoites were performed as previously
described.25
Determination of drug susceptibility in G. lamblia
Cultures with confluent trophozoite layers were incubated on ice for
15 min. Suspended motile trophozoites were counted and identical
numbers of trophozoites were inoculated into 96-well plates (0.2 mL
per well) in the presence of compound or a solvent control (DMSO). The
plates were incubated under anaerobic conditions (100% N2) at 378C
for 72 h and living trophozoites were determined by the resazurin vitality
assay as described previously.17
Overexpression of recombinant GlNR1 and GlNR2
in E. coli
For expression in BL21(DE3), cloning of GlNR1,16,17 GlNR2 (this study) and
GusA as a control17,24 as well as truncated GlNR1 and GlNR2 without fer-
redoxin domains (this study) in the E. coli His-tag expression vector
system pET151 (pET151 directional TOPO; Invitrogen) was performed
according to the manufacturer’s instructions. For expression of GlNR1,
GlNR2 and GusA in E. coli strains SOS-R1 (carrying on the chromosome
sfiA promoter fused to lacZ; kindly provided by D. F. Ackerley, School of
Biological Sciences, Victoria University of Wellington, Wellington, New
Zealand)22 and RK4353/pPnorV-lacZ-1 (carrying on the plasmid norV pro-
moter fused to lacZ; E. coli strain was kindly provided by L. M. Saraiva,
Instituto de Investigac¸a˜o, Centifica Tropical, Oeiras, Portugal; origin of
plasmid, see below),19 the expression plasmid pUCX22 (also kindly pro-
vided by D. F. Ackerley) was used. This vector contained the ampicillin re-
sistance marker for selection of transformants and allowed the
expression of recombinant proteins under the control of the strong,
IPTG-inducible tac promoter (Ptac). Ptac was regulated by a lac repressor
that is encoded by the lacIq gene located on the same plasmid.22 Reclon-
ing of the GlNR1,16 GlNR2 (this study) and GusA17,24 open reading frames
into pUCX provided plasmids pGlNR1x, pGlNR2x and pGusAx, respectively,
and was achieved by exactly following an inverse fusion PCR cloning
strategy, as recently described.26 Furthermore, plasmid pAA182-PnorV19
(kindly provided by L. M. Saraiva), containing an ampicillin resistance
marker, was used as PCR template for recloning of the PnorV:lacZ
fusion in the pCR-Blunt II TOPO vector (Invitrogen) containing a kanamy-
cin resistance marker. This recloning step provided a plasmid construct,
pPnorV-lacZ-1, suitable for subsequent transformation of ampicillin-
resistant RK4353/pGlNR1x, pGlNR2x and pGusAx strains by selection for
ampicillin (100 mg/mL)/kanamycin (50 mg/mL) double-resistant clones.
The E. coli strains and plasmids used in this study are listed in Table S1,
available as Supplementary data at JAC Online; the primers for the
corresponding PCR reactions are listed in Table S2, available as Supple-
mentary data at JAC Online.
Purification and functional assay of GlNR2
For His-tag affinity purification, the coding sequence of GlNR2 was cloned
into pET-His151 (see above). Overexpression was achieved in BL21(DE3).
His-tag purification and nitroreductase assays were performed as previ-
ously described for GlNR1.16
Determination of drug susceptibility in E. coli
Drug susceptibility of recombinant E. coli BL21(DE3) lines expressing
either GlNR1, GlNR2 or GusA were tested by a conventional disc-diffusion
agar procedure as described previously.17 For this purpose, bacteria were
grown to stationary phase (OD600¼1) in Luria–Bertani (LB) medium con-
taining 100 mg/mL ampicillin and 0.5 mM IPTG, and 0.3 mL of suspension
was streaked on LB agar plates containing 100 mg/mL ampicillin.
Whatman filter discs (5 mm diameter) were soaked with 7 mL of nitazox-
anide or metronidazole stock solutions (100 mM). The discs were air-
dried for 5 min and then placed on the plates. The plates were incubated
under aerobic or semi-aerobic (5% O2, 10% CO2, 85% N2) conditions at
378C for 24 h. Then, growth inhibition zone diameters were measured
and the inhibition zone around the disc was calculated (in mm2).
RNA analysis and quantification of gene expression
by real-time RT–PCR
For quantification of gene expression by real-time RT–PCR, trophozoites
were grown until confluence as described above. Cells were harvested
as described above and RNA was extracted using the QIAGEN RNeasy
Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instruc-
tions. RNA was eluted with RNase-free water and stored at 2808C. First-
strand cDNA was synthesized using the QIAGEN Omniscript RT Kit
(QIAGEN, Hilden, Germany). Quantitative RT–PCR was performed as
described before.17 The primers used for quantitative RT–PCR are given
in Table S1, available as Supplementary data at JAC Online. From the quan-
titative RT–PCR, mean values (+SE) from triplicate determinations were
assessed and expression levels of the GlNR1 gene were given as values
in arbitrary units relative to the amount of constitutively expressed actin.
b-Galactosidase assay in E. coli reporter strains
Liquid cultures of E. coli reporter strains SOS-R1 and RK4353/
pPnorV-lacZ-1-carrying plasmids with the nitroreductases GlNR1, GlNR2
or GusA as a control (see Table S1, available as Supplementary data at
JAC Online) were grown to early exponential phase (OD600 0.2–0.3)
and treated with metronidazole, nitazoxanide (1 mM) or DMSO as a
solvent control for an additional 150 min. Then, the OD600 was deter-
mined and b-galactosidase activity was assayed as previously
described.27 Briefly, 50 mL of each culture was added to 1 mL of PBS
buffer containing 50 mM mercaptoethanol, 20 ppm SDS and 40 mL of
chloroform. After vortexing and phase separation of the chloroform,
0.1 mL was added to the wells of a 96-well plate. Then, 0.1 mL of PBS
containing 1 mM chlorophenyl red-b-galactoside (Roche, Basel, Switzer-
land) was added; absorption at 570 nm was read at various timepoints
and the initial velocity (DA570/min) was determined. Blanks (buffer
without cells) were included and subtracted.
Statistical methods
Statistical analysis of the results was performed with suitable tools from
the open-source software package R.28 Differences exhibiting P values of
Nitroreductase and nitro drugs in G. lamblia
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,0.01 were considered significant. 50% Inhibitory concentration (IC50)
values were calculated after the logit-log transformation of the relative
growth (RG; control¼1) according to the formula ln[RG/(12RG)]¼a×
ln(drug concentration)+b followed by regression analysis.
Results
mRNA levels of the nitroreductases GlNR1 and GlNR2
in metronidazole-resistant G. lamblia strains
In order to compare nitroreductase mRNA levels of strains resist-
ant to nitro compounds, two resistant strains of WBC6 were
grown until confluence and the expression levels of the GlNR1
and GlNR2 transcripts were determined in relation to actin as a
housekeeping gene. Moreover, we included strains derived from
isolates 106 and 713 in our study. These strains are resistant
to metronidazole and to the 5-nitroimidazole C17.23 The pheno-
types of all strains were confirmed prior to our investigations. In
the WBC6 background, the mRNA levels of GlNR1 were signifi-
cantly lower in a nitazoxanide- and metronidazole-resistant
strain, clone 4 (C4), and a metronidazole-resistant strain, clone
5 (C5). In the 106 background, GlNR1 levels were significantly
lower in a strain resistant to the nitro compound C17. In the
713 background, both strains resistant to metronidazole and to
C17 had lower GlNR1 levels. Conversely, GlNR2 mRNA levels
remained unchanged in both WBC6-derived strains, C4 and C5,
and were significantly higher in the metronidazole-resistant
strains derived from 106 and 713 (Figure 2). It is, however, note-
worthy that the expression levels of both nitroreductases were
around one magnitude lower in the strains 106 and 713 than
in WBC6. Taken together, the expression profile of GlNR2 was
clearly different from that of GlNR1.
WBC6-GlNR2 is less susceptible to metronidazole than
WBC6-GusA
In a previous study, we overexpressed GlNR1 in G. lamblia WBC6
and observed an increased susceptibility to nitazoxanide and
metronidazole.17 In order to investigate whether overexpression
of GlNR2 had similar effects, we overexpressed GlNR2 in G. lamblia
WBC6. Overexpression in WBC6-GlNR2 turned out to be .10-fold
in comparison with the WBC6-GusA control strain, as verified on
the mRNA level by quantitative RT–PCR.
WBC6-GlNR2 and WBC6-GusA were grown in the presence of
the two nitro drugs nitazoxanide or metronidazole, or albenda-
zole as a control. WBC6-GlNR2 was less susceptible to metro-
nidazole than WBC6-GusA, as indicated by the corresponding
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Figure 2. mRNA levels of G. lamblia nitroreductases GlNR1 (NR1, black columns) and GlNR2 (NR2, white columns) in different isolates of G. lamblia
WBC6 and drug-resistant derivatives of these isolates. Trophozoites were grown to confluence. RNA was extracted and reverse transcribed into
cDNA. Transcripts of GlNR1 were quantified in relation to actin. Mean values+SE are given for triplicates. Values marked by asterisks are
significantly different from the control (paired t-test, two sided; **, P,0.01). (a) WBC6 and clones C4 (resistant to nitazoxanide and
metronidazole) and C5 (resistant to metronidazole). (b) Strain 106 and derivatives 106-2ID10 (resistant for metronidazole) and 106-17A (resistant
to C17). (c) Strain 713 and derivatives 713-M3 (resistant to metronidazole) and 713-M3-C17 (resistant to C17).
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IC50 values. In contrast, nitazoxanide and albendazole inhibited
the growth of both lines identically (Table 1).
Heterologous expression and functional analysis of
GlNR2
The coding sequence of GlNR2 was amplified by PCR, cloned and
expressed in E. coli. The recombinant protein was a major protein
in IPTG-induced E. coli and could further be purified by His-tag af-
finity chromatography (Figure 3a). The purified protein was sub-
jected to a nitroreductase assay based on the oxidation of NADH
in the presence of dinitrotoluene. The recombinant protein
readily reduced dinitrotoluene in a concentration-dependent
manner (Figure 3b). When metronidazole was offered as a sub-
strate, only a very low activity could be detected; when nitazox-
anide was offered as a substrate, activity was not detectable
(Figure 3c).
E. coli expressing recombinant GlNR2 exhibits decreased
susceptibility to metronidazole
The previous results suggested that GlNR2 clearly differed from
GlNR1. Whereas GlNR1 activated rather than inactivated nitro
drugs, and thus increased their efficacy (17 and this study),
GlNR2 might act in the opposite direction. In order to investigate
this hypothesis in more detail, our functional in vitro assay
system was too limited. In particular, it could not discriminate
between partial and complete reduction. Therefore, we gener-
ated recombinant E. coli lines producing GlNR1 and GlNR2
either as full-length enzymes or without ferredoxin domains, or
the control enzyme GusA. Since overproduction of proteins in
IPTG-induced E. coli strongly reduced growth, non-induced, re-
combinant E. coli cultures were chosen for growth inhibition
assays under aerobic and semi-aerobic growth conditions, as
described previously.17
Under aerobic as well as under semi-aerobic growth condi-
tions, nitazoxanide did not affect the growth of the control bac-
teria. Under semi-aerobic conditions, bacteria expressing GlNR1
were significantly more susceptible to nitazoxanide than
control bacteria, yielding inhibition zones of 30.8+4 mm2
versus ,1 mm2. Under aerobic conditions, nitazoxanide had no
inhibitory effect on bacteria expressing GlNR1, with inhibition
zones ,1 mm2. Inserts other than GlNR1 had no effect. In the
presence of metronidazole, a completely different picture was
observed. Bacteria transformed with GusA, GlNR1 or both nitror-
eductases without the ferredoxin domain were growth inhibited
under aerobic and semi-aerobic conditions. Bacteria expressing
GlNR1 exhibited a significantly higher inhibition than the others.
Interestingly, bacteria expressing GlNR2 were inhibited neither
under aerobic nor semi-aerobic growth conditions (Figure 4a
and b). Thus, GlNR1 and GlNR2 clearly had antithetical effects
in this system.
GlNR1 and GlNR2 differ with respect to nitric oxide
and DNA repair responses in E. coli
The previous results suggested that GlNR1 and GlNR2 exhibited
opposed functional properties with respect to eliciting nitric
oxide and DNA damage responses in E. coli. To test this, their
coding sequences were overexpressed in the E. coli reporter
strains RK4353/pPnorV-lacZ-1 (nitric oxide response) and
SOS-R1 (DNA repair response). Strains overexpressing GusA
were used as a control. The transformed bacteria were then
exposed to metronidazole, nitazoxanide or DMSO as a solvent
control for 150 min, harvested and b-galactosidase activity
was assessed. In RK4353/pPnorV-lacZ-1 bacteria expressing
GlNR1, b-galactosidase activity was significantly (P,0.01)
higher than in cells expressing GlNR2 or GusA, even in the ab-
sence of nitro drugs. This suggested that in cells expressing
GlNR1, the nitric oxide response was constitutively switched on.
The response was even more increased in the presence of metro-
nidazole, indicating that this compound elicited a nitric oxide re-
sponse in addition to the control (Figure 5a). The DNA repair
response was significantly increased in cells expressing GlNR1 ir-
respective of the presence, or absence, of nitro compounds
(Figure 5b). Cells expressing GlNR2 did not significantly differ
from the control in any case.
Discussion
Metronidazole and other antiparasitic nitro drugs are considered
to be prodrugs, which are activated by partial reduction forming
a toxic radical,29 or partially reduced nitroso or hydroxylamine
intermediates30 causing DNA damage.31 On the other hand,
complete reduction detoxifies nitro compounds and thus
allows some bacteria to use highly toxic compounds, such as tri-
nitrotoluene, as carbon sources.32 The overexpression of target
enzymes yielding toxic radicals would then correlate with
higher susceptibility, while the overexpression of target
enzymes performing a total reduction would result in increased
resistance. Our results presented above suggest that G. lamblia
expresses two nitroreductases with functional activities
working in both directions. GlNR1 is one of the enzymes with
the ability to partially reduce nitro compounds to toxic inter-
mediates, since it was shown that overexpression of GlNR1 in
G. lamblia is followed by higher susceptibilities to both metro-
nidazole and nitazoxanide.17 Conversely, strains resistant to nita-
zoxanide and/or metronidazole express GlNR1 at lower levels, as
shown previously11,17 and in this study. The observation that
C17-resistant cell lines do not express higher levels of GlNR2
Table 1. Drug susceptibility of G. lamblia WBC6 expressing E. coli
b-glucuronidase A (GusA) and of G. lamblia nitroreductase (GlNR2)
Drug
IC50 mM (95% CI)
G. lamblia GusA G. lamblia GlNR2
Metronidazole 1.7 (1.4–2.1) 4.8 (3.5–6.5)
Nitazoxanide 0.7 (0.6–0.8) 0.7 (0.6–0.8)
Albendazole 0.03 (0.02–0.0) 0.04 (0.03–0.05)
Ninety-six-wellplateswere inoculatedwith103 trophozoitesofGusAorGlNR2
trophozoites per well and grown in the presence of metronidazole,
nitazoxanide, or albendazole at various concentrations. After 72 h, the
growth of cells was monitored by a vitality assay based on the reduction of
resazurin (Alamar blue) to a pink product that was assayed fluorimetrically.
IC50 values were determined after logit-log transformations of the data.
Nitroreductase and nitro drugs in G. lamblia
1785
JAC
 at W
orld Trade Institute on A
ugust 6, 2014
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
may be explained by the fact that the 5-nitroimidazole C17 is
metabolized differently from other nitroimidazoles, including
metronidazole.23 The overexpression of GlNR2, however, does
not affect the susceptibility to nitazoxanide, but decreases the
susceptibility to metronidazole. In resistant strains, its expression
levels remain unchanged or are even increased. These results
suggest that GlNR2 detoxifies rather than activates nitro com-
pounds, e.g. by complete reduction to less toxic amines.
The results obtained with E. coli are of particular interest, since
they indicate that GlNR1 and GlNR2 work in a different cellular en-
vironment in the same way as in Giardia (at least with respect to
nitro drugs). E. coli expressing GlNR1 and GlNR2 without a ferre-
doxin domain have no phenotypes different from the control, sug-
gesting that this domain is essential for their activities. GlNR1
enhances the susceptibility to nitazoxanide under semi-aerobic
conditions but not under aerobic conditions and to metronidazole
under both growth conditions. GlNR2 decreases the susceptibility
tometronidazole under both growth conditions. This corroborates
our previous findings that recombinant GlNR1 does not reduce
nitazoxanide in vitro under aerobic conditions11 and our present
in vitro results with the recombinant GlNR2. Moreover, our results
suggest that in E. coli BL21(DE3), the strain used in these experi-
ments, endogenous nitroreductases are expressed even under
aerobic growth conditions, which is fully consistentwith previously
published results.20,21,33While these endogenous nitroreductases
reduce metronidazole to toxic intermediates, GlNR2 detoxifies
them, thus eliminating metronidazole toxicity against E. coli. The
fact that E. coli BL21(DE3) is susceptible to metronidazole has
been reported earlier.17,34 These results can, however, not be
extended to other E. coli strains, e.g. SOS-R1 is non-susceptible
to metronidazole under aerobic as well as semi-aerobic growth
conditions (data not shown).
The results with the E. coli reporter strains for nitric oxide re-
sponse (RK4353/pAA182-PnorV) and DNA damage (SOS-R1)
confirm that GlNR1 and GlNR2 have a different mode of action
and add an important novel facet. Even in the absence of nitro
drugs, GlNR1 elicits responses in both systems whereas GlNR2
does not. This may be explained by a direct activation of the
sensors in both systems or the presence of nitro compounds in
the complex culture medium that are activated by GlNR1, but
not by GlNR2. A good candidate may be nitrite,35 which would
be reduced to nitric oxide by GlNR1, but not by GlNR2.
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Figure 3. Heterologous expression in E. coli BL21(DE3) and functional assay of GlNR2. (a) SDS–PAGE of His-tag-purified recNR2. M, markers with sizes in
kDa; lane 1, crude extract; lane 2, flow through; lane 3, wash; lane 4, wash with 10 mM imidazole; and lanes 5 and 6, fractions eluted with 200 mM
imidazole. (b) Functional assay of fraction 5 in the presence of increasing concentrations of dinitrotoluene (DNT). (c) Functional assay in the presence
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Taken together, these results suggest the following modes of
action of both nitroreductases: (i) the essential ferredoxin
domain transfers electrons from a donor (NADH) to the FMN in
the active centre; (ii) in the case of GlNR1, the nitro compound
is partially reduced, yielding toxic intermediates; and (iii) in the
case of GlNR2, the nitro compound is entirely reduced yielding
a non-toxic end product, e.g. the corresponding amine.
From an evolutionary point of view, the presence of functional
and constitutively expressed nitroreductases in G. lamblia should
represent at least one selective advantage. Otherwise, the re-
spective sequences would be full of missense, or nonsense,
mutations or have been deleted during evolution. These selective
advantages could be: (i) inactivation of nitric oxide produced by
endogenous processes (from L-arginine) or by the host; (ii) inacti-
vation of nitroso or hydroxylamine intermediates present in the
digestive tract; and (iii) utilization of naturally occurring nitrous
compounds as alternative electron acceptors. These issues
have been extensively discussed in the literature.36
In intestinal epithelial cells, the predominant nitric oxide bio-
synthetic pathway involves the inducible nitric oxide synthase
converting free L-arginine into citrulline and nitric oxide.37
Several publications suggest that nitric oxide produced in intes-
tinal epithelium cells is a major defence molecule against
Giardia infections. In vitro, nitric oxide inhibits the proliferation
of trophozoites as well as cyst formation.38 However, the effect-
iveness of nitric oxide against a giardial infection may be
affected by the depletion of L-arginine as a consequence of a
high-affinity uptake of the compound by the parasite38 followed
by degradation through two L-arginine-metabolizing enzymes
(arginine deiminase and ornithine carbamoyl transferase)
released by the parasite upon contact with host cells.39,40
Under anaerobic conditions, nitroreductases may be candidates
for the detoxification of endogenous, or exogenous, nitric
oxide. Furthermore, nitroreductases may also be involved in the
detoxification of nitroso compounds accumulating in the intes-
tinal tract, particularly as a consequence of a red meat-enriched
diet.41 Such compounds may be generated at biological haem
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centres mediating, e.g. the nitration of phenol and tryptophan.42
Detoxification is, however, achieved only if the reduction of these
compounds is complete. GlNR1 alone creates toxic intermedi-
ates; GlNR2 alone or together with GlNR1 would then achieve
detoxification.
One should keep in mind, however, that the responses to nitric
oxide and to nitro compounds may not be identical given the
complexity of the associated chemical and biochemical reac-
tions.36 Differential transcriptomic and proteomic analyses43 of
suitable organisms (e.g. E. coli) expressing heterologous nitrore-
ductases versus suitable controls may help in disclosing the
roles of these enzymes.
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